BioCryst Pharmaceuticals (BCRX) Files $70M Mixed Securities Shelf
More News related to BCRX
- Russell Index Additions See Upside Action On Reconstitution (BWEN, TZOO, MTXX, DDRX, MSSR)
- WHO Raises Swine Flu Alert Level To 6
- WHO to Hold Meeting of Pandemic Emergency Committee on Thursday as Swine Flu is Dangerously Close to 'Phase 6'
- Top 10 News Items 6/1-6/5: GM IS BANKRUPT; Jobs Report Comes in Much Better-Than-Expected; Equity Offerings Still All The Rage
- WHO: Swine Flu Situation is 'Moving Closer to Phase 6'
In a Form S-3 after the close on Friday, BioCryst Pharmaceuticals (Nasdaq: BCRX) announced that it may, from time to time, offer $70 million worth of securities to the public. The securities include common stock, preferred stock, warrants and units, etc.
BioCryst Pharmaceuticals, Inc., a biotechnology company, engages in the design, optimization, and development of novel drugs that block enzymes involved in cancer, viral infections, cardiovascular diseases, and autoimmune diseases.
Related Categories
Equity OfferingsStocks Mentioned
+0.06Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
